Clinical Trial Update: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma [Phase 1]

View source ↗

Summary

The Phase I trial of vandetanib in combination with 131I-mIBG for advanced pheochromocytoma and paraganglioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• 131I-MIBG (metaiodobenzylguanidine)
• Vandetanib (vandetanib)

Snippet

Sponsor: University College, London | Conditions: Phaeochromocytoma, Paraganglioma | Phase 1 | Status: WITHDRAWN